Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Haw Par Corporation Limited (H02.SI)
Singapore, SG
Established in Singapore in 1969, Haw Par Corporation Limited specializes in the manufacturing, marketing, and global trade of healthcare products, serving markets in Singapore, ASEAN countries, other Asian regions, and beyond. The company's business activities are structured into three main segments: Healthcare, Investments, and Others. Its Healthcare segment primarily produces and distributes topical pain relief solutions, prominently featuring the Tiger Balm and Kwan Loong brands. The Investments segment focuses on acquiring publicly traded securities. Additionally, Haw Par owns and leases out a diverse portfolio of investment properties, comprising 45,324 square meters of commercial and industrial real estate across Singapore and Malaysia. The corporation also offers family and tourist-oriented leisure experiences, notably through oceanariums. Furthermore, it provides leasing services for land, buildings, and office spaces, in addition to offering management support.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.20% | -7.61% | -10.40% | -7.66% | +0.59% | -1.66% | +30.57% | +65.81% | +14.82% | +75.23% | +776.14% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%-6.1% Q4'25: -14.3% (vs Q4'23)
-
EPS growth Drug Manufacturers - General: +18.2%+16.5% Q4'25: +7.8% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+22.3% Q4'25: +120.7% (vs Q4'23)
-
EBIT margin Drug Manufacturers - General: +19.4%+29.2% ★ Q4'25: +32.7% (vs Q4'23)
-
ROIC Drug Manufacturers - General: +10.2%+1.8% Q4'25: +3.6% (vs Q4'23)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q4'25: +0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.60× ★ Q4'25: 0.30× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
237.81M
est: 249.50M (-4.7%)
|
243.99M
est: 277.00M (-11.9%)
|
244.68M
244.68M – 244.68M
-11.7% YoY
|
260.46M
260.46M – 260.46M
+6.4% YoY
|
| EBITDA |
88.59M
est: 205.36M (-56.9%)
|
85.72M
est: 228.00M (-62.4%)
|
168.09M
168.09M – 168.09M
-26.3% YoY
|
178.93M
178.93M – 178.93M
+6.4% YoY
|
| EBIT |
83.26M
est: 200.36M (-58.4%)
|
78.93M
est: 222.44M (-64.5%)
|
161.83M
161.83M – 161.83M
-27.2% YoY
|
172.27M
172.27M – 172.27M
+6.4% YoY
|
| Net Income |
179.07M
|
182.21M
|
276.16M
276.16M – 276.16M
|
283.89M
283.89M – 283.89M
+2.8% YoY
|
| SGA |
62.48M
est: 77.66M (-19.6%)
|
60.19M
est: 86.22M (-30.2%)
|
73.91M
73.91M – 73.91M
-14.3% YoY
|
78.67M
78.67M – 78.67M
+6.4% YoY
|
| EPS |
0.81
|
0.82
|
1.25
1.25 – 1.25
|
1.28
1.28 – 1.28
+2.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-25 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 4/5 | 3/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers MSCI Singapore UCITS ETF 1C O9A.SI | 0.38% | 441.9K | 0.50% |
| 2 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.15% | 108.6K | 0.74% |
| 3 | Schwab International Small-Cap Equity ETF SCHC | 0.07% | 3.70M | 0.06% |
| 4 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.05% | 103.0K | 0.83% |
| 5 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.05% | 6.21M | 0.40% |
| 6 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.04% | 6.07M | 0.06% |
| 7 | iShares Core MSCI Pacific ETF IPAC | 0.02% | 489.2K | 0.09% |
| 8 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.01% | 31.2K | 0.22% |
| 9 | Vanguard FTSE Pacific ETF VPL | 0.01% | 1.74M | 0.07% |
| 10 | FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD | 0.01% | 78.4K | 0.41% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ee Lim Wee | Chief Executive Officer, President & Executive Non-Independent Director | 3M | male |
| Cindy Ow | Director of Human Resource | — | female |
| Kun Long Chiew | Group Finance Manager & Company Secretary | — | male |
| Meng Tiam Kwek | Regional General Manager of Underwater World Singapore Pte Ltd & Haw Par Leisure Pte Ltd | — | male |
| Mui Lick Kow | Head of Quality & Regulatory Affairs | — | male |
| Say Suan Chow | Chief Financial Officer | — | male |
| Brian Loo | Group General Manager | — | male |
| Tang Ling Lee | Manager of Corporate Communications | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for H02.SI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
